Background
Methods
Corset group | No corset group | All | |||||
---|---|---|---|---|---|---|---|
n
| % |
n
| % |
n
| % | ||
Age (mean, SD) | 63.2 (+/− 11.4) | 62.2 (+/−10.8) | 62.7 (+/−11.1) | ||||
Gender | male | 236 | 53.4 | 253 | 53.5 | 489 | 53.4 |
female | 206 | 46.6 | 220 | 46.5 | 426 | 46.6 | |
KPS | <=70 | 204 | 46.2 | 218 | 46.1 | 422 | 46.1 |
>70 | 238 | 53.8 | 255 | 53.9 | 493 | 53.9 | |
Primary site | NSCLC | 101 | 22.9 | 206 | 43.5 | 425 | 46.5 |
Breast | 219 | 49.6 | 74 | 15.6 | 175 | 19.1 | |
Kidney | 71 | 16.1 | 88 | 18.6 | 159 | 17.4 | |
Melanoma | 15 | 3.4 | 26 | 5.5 | 41 | 4.5 | |
Prostate | 4 | 0.9 | 13 | 2.8 | 17 | 1.9 | |
Other | 51 | 11.5 | 105 | 22.2 | 98 | 10.6 | |
Localization | Thoracic | 284 | 64.3 | 279 | 59.0 | 563 | 61.5 |
Lumbar | 158 | 35.7 | 194 | 41.0 | 352 | 38.5 | |
Chemotherapy | yes | 242 | 54.7 | 260 | 55.1 | 502 | 54.9 |
no | 200 | 45.3 | 212 | 44.9 | 412 | 45.1 | |
Stability before RT | stable | 140 | 31.7 | 320 | 67.7 | 460 | 50.3 |
unstable | 302 | 68.3 | 153 | 32.3 | 455 | 49.7 | |
Stability after 3 months | stable | 152 | 39.8 | 279 | 79.0 | 449 | 59.2 |
unstable | 230 | 60.2 | 79 | 21.0 | 309 | 40.8 | |
Stability after 6 months | stable | 165 | 45.1 | 311 | 85.2 | 476 | 65.1 |
unstable | 201 | 54.9 | 54 | 14.8 | 255 | 34.9 | |
Bisphosphonates | yes | 351 | 79.4 | 296 | 62.6 | 647 | 70.7 |
no | 91 | 20.6 | 177 | 37.4 | 268 | 29.3 | |
Distant metastases | Brain | 50 | 11.3 | 77 | 16.3 | 127 | 13.9 |
Lung | 74 | 16.7 | 118 | 25.0 | 192 | 21.0 | |
Liver | 70 | 15.8 | 116 | 24.5 | 186 | 20.3 | |
Skin | 11 | 2.5 | 25 | 5.3 | 36 | 3.9 | |
Number of metastases | solitary | 189 | 42.8 | 228 | 48.2 | 417 | 45.6 |
multiple | 253 | 57.2 | 245 | 51.8 | 498 | 54.4 |
Statistical analysis
Radiotherapy
Results
All | Corset group | No corset group | p-value | |||||
---|---|---|---|---|---|---|---|---|
n
| % |
n
| % |
n
| % | between groups | ||
Pathological fracture | yes | 68 | 7.4 | 30 | 6.8 | 38 | 8.0 | |
before RT | no | 847 | 92.6 | 412 | 93.2 | 435 | 92.0 | 0.473 |
thoracic | 42 | 61.8 | 22 | 73.3 | 20 | 52.6 | ||
lumbar | 26 | 38.2 | 8 | 26.7 | 18 | 47.4 | 0.081 | |
Pathological fracture | yes | 82 | 9.0 | 38 | 8.6 | 44 | 9.3 | |
after 6 months | no | 833 | 91.0 | 404 | 91.4 | 429 | 90.7 | 0.709 |
thoracic | 51 | 62.2 | 28 | 73.7 | 23 | 52.3 | ||
lumbar | 31 | 37.8 | 10 | 26.3 | 21 | 47.7 | 0.046 |
Factor | Corset group | No corset group |
---|---|---|
p-value | p-value | |
Gender | 0.357 | 0.642 |
KPS | 0.402 | 0.819 |
NSCLC | 0.101 | 0.184 |
Breast cancer | 0.496 | 0.091 |
Kidney cancer | 0.072 | 0.195 |
Localization | 0.205 | 0.342 |
Chemotherapy | 0.454 | 0.379 |
Stability before RT | 0.268 | 0.677 |
Stability after 3 months | 0.513 | 0.614 |
Stability after 6 months | 0.202 | 0.402 |
Bisphosphonates | 0.183 | 0.420 |
Number of metastases | 0.145 | 0.229 |
All | Corset group | No corset group | |||||||
---|---|---|---|---|---|---|---|---|---|
OR | 95 % CI | p-value | OR | 95 % CI | p-value | OR | 95 % CI | p-value | |
Gender | 0.797 | 0.503–1.262 | 0.333 | 0.727 | 0.369–1.434 | 0.358 | 0.862 | 0.461–1.612 | 0.642 |
KPS | 0.843 | 0.535–1.327 | 0.461 | 0.753 | 0.387–1.465 | 0.403 | 0.930 | 0.500–1.731 | 0.819 |
NSCLC | 0.604 | 0.376–0.969 | 0.036 | 0.566 | 0.285–1.126 | 0.105 | 0.645 | 0.336–1.237 | 0.186 |
Breast cancer | 0.562 | 0.284–1.113 | 0.098 | 0.745 | 0.318–1.746 | 0.498 | 0.369 | 0.111–1.225 | 0.103 |
Kidney cancer | 1.071 | 0.595–1.928 | 0.818 | 2.008 | 0.928–4.345 | 0.076 | 0.534 | 0.204–1.398 | 0.202 |
Localization | 0.970 | 0.607–1.548 | 0.897 | 0.618 | 0.292–1.308 | 0.208 | 1.351 | 0.725–2.517 | 0.343 |
Chemotherapy | 1.020 | 0.647–1.609 | 0.931 | 1.295 | 0.657–2.555 | 0.455 | 1.329 | 0.704–2.511 | 0.381 |
Stability before RT | 0.937 | 0.595–1.474 | 0.777 | 0.647 | 0.298–1.406 | 0.271 | 1.155 | 0.586–2.276 | 0.677 |
Stability after 3 months | 0.993 | 0.594–1.660 | 0.980 | 0.776 | 0.363–1.660 | 0.514 | 1.266 | 0.505–3.174 | 0.614 |
Stability after 6 months | 0.939 | 0.537–1.642 | 0.826 | 0.587 | 0.256–1.343 | 0.207 | 1.682 | 0.493–5.740 | 0.406 |
Bisphosphonates | 0.939 | 0.573–1.538 | 0.803 | 0.606 | 0.288–1.274 | 0.186 | 1.313 | 0.676–2.550 | 0.421 |
Number of metastases | 1.314 | 0.826–2.090 | 0.249 | 1.689 | 0.829–3.442 | 0.149 | 0.683 | 0.365–1.277 | 0.232 |